Effect of Atazanavir/Ritonavirin treatment of COViD-19

Evaluation of Atazanavir/Ritonavir effect on COViD-19 patients treatment in comparison with Lopinavir / Ritonavir

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200504047298N1

Enrollment

100

Registered

2020-06-14

Start date

2020-06-14

Completion date

Unknown

Last updated

2020-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COViD-19. Use this code when COVID-19 has been confirmed by laboratory testing irrespective of severity of clinical signs or symptoms. Use additional code, if desired, to identify pneumonia or other manifestations.

Interventions

Intervention 1: Intervention group: Atazanavir/ritonavir treatment group will receive 300/100 mg of each drug for 14 days once a day. It will be prescribed as tablets. Intervention 2: Control group: L

Eligibility

Sex/Gender

All

Age

20 Years to 80 Years

Inclusion criteria

Inclusion criteria: all COViD-19 patients aged between 20-80

Exclusion criteria

Exclusion criteria: low blood pressure Nausea Vomiting Dysuria Paleness Low mental status poor collaboration

Design outcomes

Primary

Measure	Time frame
COViD-19 patients clinical progression. Timepoint: frequently in hospitalization time. Method of measurement: need to be intubated, body temperature, heart rate, respiratory rate, cough, dyspnea, ICU admission.;COViD-19 patients para-clinical progression. Timepoint: frequently in hospitalization time. Method of measurement: O2 saturation, CBC, inflammatory biomarkers (ESR, CRP).	—

Secondary

Measure	Time frame
O2 saturation. Timepoint: all along the hospitalization. Method of measurement: Pulse oxymeter.;Temperature. Timepoint: All along the hospitalization. Method of measurement: Thermometer.;Heart rate. Timepoint: All along the hospitalization. Method of measurement: clinical examination.;Respiratory rate. Timepoint: All along the hospitalization. Method of measurement: Clinical examination.;Chest Imaging. Timepoint: Along the hospitalization. Method of measurement: Chest X-ray, CT scan.;ECG. Timepoint: Along the hospitalization. Method of measurement: 12-Lead ECG tool.;Coughing. Timepoint: along the hospitalization. Method of measurement: inspection and examination.;ICU admission. Timepoint: Along the hospitalization. Method of measurement: Documents.;Hospitalization duration. Timepoint: daily. Method of measurement: documents.;Blood Pressure. Timepoint: Along the hospitalization. Method of measurement: Barometer.	—

Measure

Time frame

O2 saturation. Timepoint: all along the hospitalization. Method of measurement: Pulse oxymeter.;Temperature. Timepoint: All along the hospitalization. Method of measurement: Thermometer.;Heart rate. Timepoint: All along the hospitalization. Method of measurement: clinical examination.;Respiratory rate. Timepoint: All along the hospitalization. Method of measurement: Clinical examination.;Chest Imaging. Timepoint: Along the hospitalization. Method of measurement: Chest X-ray, CT scan.;ECG. Timepoint: Along the hospitalization. Method of measurement: 12-Lead ECG tool.;Coughing. Timepoint: along the hospitalization. Method of measurement: inspection and examination.;ICU admission. Timepoint: Along the hospitalization. Method of measurement: Documents.;Hospitalization duration. Timepoint: daily. Method of measurement: documents.;Blood Pressure. Timepoint: Along the hospitalization. Method of measurement: Barometer.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZeinab Siami

Alborz University of Medical Sciences

z.siami@abzums.ac.ir+98 26 3252 7575

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026